Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®GlobeNewsWire • 06/08/26
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®GlobeNewsWire • 06/04/26
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq IcelandGlobeNewsWire • 06/01/26
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/14/26
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik FacilityGlobeNewsWire • 05/11/26
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar PlayerSeeking Alpha • 04/10/26
ROSEN, LEADING INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVONewsfile Corp • 02/11/26